News

By promoting the development, coordination and sharing of research resources and expertise, these awards expand research opportunities and increase the number of competitive investigators in 23 eligible states

Two new fully segregated state-of-the-art viral product manufacturing suites will be built to employ the latest in disposable bioreactor technologies and enable SAFC Pharma’s viral manufacturing to increase

The new investment will support further development of Pervasis’s innovative Vascugel blood vessel repair therapeutic, presently in two Phase II clinical trials, as well as continuing research into

The financing gives the company the right to place common stock to the investors at a 3% discount to the market price of the company’s stock. Paul Averback,

This expanded program is funded by and coordinated with Meda, BDSI’s US and European commercial partner for Bema Fentanyl. Under this new program, BDSI and Meda plan to

Glipizide or Metformin HCl is indicated as initial therapy, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes whose hyperglycemia

Health Canada’s approval of Eloxatin was based on clinical data collected over several years. The MOSAIC trial compared the efficacy and evaluated the safety of Eloxatin in combination

The approved patent protects the composition and method behind the company’s oral probiotic product formulation Kibow Biotics, which may significantly reduce concentrations of several nitrogenous waste metabolites that

Under the agreement, VWR will distribute Axela’s proprietary dotLab system and reagents across North America. This arrangement significantly expands VWR’s instrumentation offerings in the protein research sector. Axela’s